Why should albumin be discontinued in a cirrhotic patient with ascites who does not have spontaneous bacterial peritonitis?

Why Albumin is Discontinued Without SBP

Albumin should be discontinued in cirrhotic patients with ascites who do not have spontaneous bacterial peritonitis because albumin is only indicated for specific, evidence-based complications—not for routine ascites management—and continuing it outside these indications increases the risk of pulmonary edema and fluid overload without improving mortality or quality of life.

Evidence-Based Indications for Albumin in Cirrhosis

The 2024 AGA guidelines 1 and FDA labeling 2 clearly define when albumin is appropriate:

Established Indications:

• Spontaneous bacterial peritonitis (SBP) - with antibiotics to prevent renal impairment and reduce mortality
• Large-volume paracentesis - to prevent paracentesis-induced circulatory dysfunction
• Hepatorenal syndrome-AKI - with vasoconstrictors (terlipressin or norepinephrine)
• Acute kidney injury with volume depletion - 1 g/kg daily for 2 days (max 100 g/day)

NOT Indicated:

• Uncomplicated ascites without the above complications
• Chronic hypoproteinemia from cirrhosis
• Routine maintenance of serum albumin levels

Why Discontinuation is Critical Without SBP

Risk of Harm Without Benefit

The landmark ATTIRE trial (referenced in 1, 3) randomized 777 hospitalized cirrhotic patients to daily albumin infusions targeting serum albumin ≥3.0 g/dL versus standard care. The albumin group received 10 times more albumin but showed:

• No reduction in infection, renal failure, or death
• Significantly higher rates of pulmonary edema 1
• Increased fluid overload complications 3

This demonstrates that targeting albumin levels or using albumin prophylactically causes harm without improving outcomes.

FDA Labeling Explicitly States

The FDA drug label 2 clearly states: "in hypoproteinemic states associated with chronic cirrhosis...the infusion of albumin as a source of protein nutrition is not justified."

Clinical Decision Algorithm

When to CONTINUE albumin:

1. Active SBP diagnosis (PMN count >250/mm³) → Continue with antibiotics 4, 5, 6
2. Post-large-volume paracentesis (>5L removed) → Give 6-8 g per liter removed
3. Hepatorenal syndrome-AKI → Continue with vasoconstrictors
4. AKI with documented volume depletion → 2-day course only

When to DISCONTINUE albumin:

1. Negative paracentesis (PMN <250/mm³) - no SBP present
2. Completion of 2-day course for AKI
3. Uncomplicated ascites on diuretics alone
4. Any signs of volume overload (pulmonary edema, dyspnea, hypoxia)

Common Pitfalls to Avoid

Pitfall #1: Continuing albumin "to maintain levels"

• Serum albumin levels do NOT guide therapy in chronic cirrhosis 1
• The ATTIRE trial proved this approach increases pulmonary complications without benefit

Pitfall #2: Using albumin for all infections

• A 2015 RCT 7 showed albumin for non-SBP infections (pneumonia, UTI) delayed renal failure onset but did NOT improve 3-month survival or renal function
• 8.3% developed pulmonary edema, with 2 deaths directly related to albumin infusion
• Only SBP has proven mortality benefit with albumin 8, 9

Pitfall #3: Ignoring volume status

• The 2024 AASLD guidance 3 emphasizes that fixed albumin dosing can cause volume overload
• Monitor for signs: increasing oxygen requirements, crackles on exam, worsening peripheral edema

The Pathophysiologic Rationale

Why albumin works in SBP but not uncomplicated ascites:

In SBP, bacterial infection triggers intense systemic inflammation and vasodilation, causing:

• Acute circulatory dysfunction
• Rapid decline in effective arterial blood volume
• High risk of hepatorenal syndrome

Albumin in this setting provides both volume expansion AND anti-inflammatory effects 3.

In uncomplicated ascites, the problem is chronic sodium retention from portal hypertension—albumin does not address this mechanism and simply adds volume that cannot be effectively cleared 1.

Bottom Line for Practice

Discontinue albumin immediately when:

• Diagnostic paracentesis is negative for SBP
• The specific indication (LVP, HRS-AKI) has been completed
• Any signs of fluid overload develop

The evidence is clear: albumin outside proven indications increases morbidity (pulmonary edema) without improving mortality or quality of life 1, 3, 7. The 2024 guidelines 1 explicitly state "the exact population that will benefit from albumin beyond its use with LVP, SBP, and AKI remains to be determined"—meaning routine use is not supported.